Literature DB >> 1335280

Coordinate expression of Wilms' tumor genes correlates with Wilms' tumor phenotypes.

H Yeger1, C Cullinane, A Flenniken, S Chilton-MacNeil, C Campbell, A Huang, L Bonetta, M J Coppes, P Thorner, B R Williams.   

Abstract

The cloning and molecular characterization of two putative tumor genes, WT1 and WIT1, from the chromosome 11p13 region has provided a means of evaluating their role in the generation of Wilms' tumor heterogeneity. A series of 29 tumors were analyzed for WT1 and WIT1 expression by Northern blot or RNase protection analyses, and results were compared with tumor histopathology. Tumors were scored for the percentage of mesenchymal and epithelial derived tissue components. Homotypic tumors comprised blastema, tubular epithelium, and a fibroblast-like mesenchyme. In addition to these tissue components, the group of tumors designated as heterotypic also contained ectopic cell phenotypes such as muscle and squamous epithelium. The analyses suggest that heterotypic differentiation patterns occur when WT1 and WIT1 expression is low relative to normal fetal kidney. In situ hybridization using antisense RNA probes showed that WT1 and WIT1 were concordantly expressed in normal fetal kidney and in the blastema of tumors. The ratio of WT1:WIT1 expression remained relatively constant in homotypic tumors but deviated significantly in heterotypic tumors. These results suggest that expression patterns of the WT1 and WIT1 genes can be closely correlated to Wilms' tumor histopathology.

Entities:  

Mesh:

Year:  1992        PMID: 1335280

Source DB:  PubMed          Journal:  Cell Growth Differ        ISSN: 1044-9523


  11 in total

1.  Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation.

Authors:  Y Ye; B Raychaudhuri; A Gurney; C E Campbell; B R Williams
Journal:  EMBO J       Date:  1996-10-15       Impact factor: 11.598

2.  Analysis of WT1 gene expression during mouse nephrogenesis in organ culture.

Authors:  H Yeger; D Forget; J Alami; B R Williams
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-09       Impact factor: 2.416

3.  The role of NF-kappaB in the regulation of the expression of wilms tumor suppressor gene WT1.

Authors:  Y Chen; B R Williams
Journal:  Gene Expr       Date:  2000

4.  Correlation of germ-line mutations and two-hit inactivation of the WT1 gene with Wilms tumors of stromal-predominant histology.

Authors:  V Schumacher; S Schneider; A Figge; G Wildhardt; D Harms; D Schmidt; A Weirich; R Ludwig; B Royer-Pokora
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-15       Impact factor: 11.205

5.  Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome.

Authors:  C Lahoti; P Thorner; D Malkin; H Yeger
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

6.  novH: differential expression in developing kidney and Wilm's tumors.

Authors:  G Chevalier; H Yeger; C Martinerie; M Laurent; J Alami; P N Schofield; B Perbal
Journal:  Am J Pathol       Date:  1998-06       Impact factor: 4.307

7.  Homozygous somatic Wt1 point mutations in sporadic unilateral Wilms tumor.

Authors:  M J Coppes; G J Liefers; P Paul; H Yeger; B R Williams
Journal:  Proc Natl Acad Sci U S A       Date:  1993-02-15       Impact factor: 11.205

8.  Alternately spliced WT1 antisense transcripts interact with WT1 sense RNA and show epigenetic and splicing defects in cancer.

Authors:  Anthony R Dallosso; Anne L Hancock; Sally Malik; Ashreena Salpekar; Linda King-Underwood; Kathy Pritchard-Jones; Jo Peters; Kim Moorwood; Andrew Ward; Karim T A Malik; Keith W Brown
Journal:  RNA       Date:  2007-10-16       Impact factor: 4.942

Review 9.  Tumor suppressor genes and their roles in breast cancer.

Authors:  L A Cox; G Chen; E Y Lee
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 10.  Towards an understanding of Wilms' tumour.

Authors:  K A Williamson; V Van Heyningen
Journal:  Int J Exp Pathol       Date:  1994-06       Impact factor: 1.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.